CTLA4 and neoplasm: Combining immune checkpoint inhibitors such as anti-CTLA4 and anti-PD1 mAbs can have dramatic effects on anti-tumor immune responses, and result in significant improvements in clinical outcomes, compared with single antibody treatment[54].